Gilead Sciences (GILD) call put ratio 2.3 calls to 1 put after FT says remdesivir failed in first trial
Tweet
Share
E-mail
Get Alerts GILD Hot Sheet
Price: $125.72 +0.68%
Overall Analyst Rating:
SELL (= Flat)
Dividend Yield: 2.3%
EPS Growth %: -462.7%
Overall Analyst Rating:
SELL (= Flat)
Dividend Yield: 2.3%
EPS Growth %: -462.7%
Join SI Premium – FREE
Gilead Sciences (NASDAQ: GILD) 30-day option implied volatility is at 52; compared to its 52-week range of 19 to 108 after FT says remdesivir failed in first trial. Call put ratio 2.3 calls to 1 put.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Apollo Global Management (APO) call put ratio 1 call to 6.8 puts a focus on a spreader of 9K contracts January 95 and 135 puts
- IBM (IBM) call put ratio 9.7 calls to 1 put with a focus on August and September 285 calls
- SPS Commerce (SPSC) 400 contracts of July 60 calls trade
Create E-mail Alert Related Categories
OptionsRelated Entities
OptionsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
